In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim

被引:6
|
作者
Sips, Fianne L. P. [1 ]
Pappalardo, Francesco [2 ,3 ]
Russo, Giulia [2 ,3 ]
Bursi, Roberta [1 ]
机构
[1] InSilicoTrials Technol, Shertogenbosch, Netherlands
[2] Univ Catania, Dept Drug & Hlth Sci, Catania, Italy
[3] Mimesis Srl, Catania, Italy
关键词
Relapsing-Remitting Multiple Sclerosis; In silico trials; Digital patient; Computational modeling and simulation; Study design; NATALIZUMAB;
D O I
10.1186/s12911-022-02034-x
中图分类号
R-058 [];
学科分类号
摘要
Background The last few decades have seen the approval of many new treatment options for Relapsing-Remitting Multiple Sclerosis (RRMS), as well as advances in diagnostic methodology and criteria. These developments have greatly improved the available treatment options for today's Relapsing-Remitting Multiple Sclerosis patients. This increased availability of disease modifying treatments, however, has implications for clinical trial design in this therapeutic area. The availability of better diagnostics and more treatment options have not only contributed to progressively decreasing relapse rates in clinical trial populations but have also resulted in the evolution of control arms, as it is often no longer sufficient to show improvement from placebo. As a result, not only have clinical trials become longer and more expensive but comparing the results to those of "historical" trials has also become more difficult. Methods In order to aid design of clinical trials in RRMS, we have developed a simulator called MS TreatSim which can simulate the response of customizable, heterogeneous groups of patients to four common Relapsing-Remitting Multiple Sclerosis treatment options. MS TreatSim combines a mechanistic, agent-based model of the immune-based etiology of RRMS with a simulation framework for the generation and virtual trial simulation of populations of digital patients. Results In this study, the product was first applied to generate diverse populations of digital patients. Then we applied it to reproduce a phase III trial of natalizumab as published 15 years ago as a use case. Within the limitations of synthetic data availability, the results showed the potential of applying MS TreatSim to recreate the relapse rates of this historical trial of natalizumab. Conclusions MS TreatSim's synergistic combination of a mechanistic model with a clinical trial simulation framework is a tool that may advance model-based clinical trial design.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
    Fianne L. P. Sips
    Francesco Pappalardo
    Giulia Russo
    Roberta Bursi
    [J]. BMC Medical Informatics and Decision Making, 22
  • [2] Relapsing-remitting multiple sclerosis
    Flores, A
    Ochoa, E
    Zamora, S
    Barrientos, UN
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 110 - 110
  • [3] A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics
    Solomon, Andrew J.
    Bernat, James L.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 7 : 109 - 112
  • [4] Autohemotherapy for relapsing-remitting multiple sclerosis
    Mubaidin, AF
    Horani, KA
    Dehayyat, MA
    Shehab, M
    Abu-Ruman, IA
    Shurbaji, AA
    Kurdi, A
    Hiari, M
    Khakish, M
    Harahsheh, O
    Dabbas, M
    [J]. NEUROLOGY, 2001, 56 (08) : A75 - A75
  • [5] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [6] Relapsing-remitting tumefactive multiple sclerosis
    Selkirk, SM
    Shi, J
    [J]. MULTIPLE SCLEROSIS, 2005, 11 (06): : 731 - 734
  • [7] Depression in relapsing-remitting multiple sclerosis
    Mendes, MF
    Tilbery, CP
    Balsimelli, S
    Moreira, MA
    Barao-Cruz, AM
    [J]. ARQUIVOS DE NEURO-PSIQUIATRIA, 2003, 61 (3A) : 591 - 595
  • [8] Rituximab in relapsing-remitting multiple sclerosis
    Schrijver, Hans M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24): : 2645 - 2645
  • [9] Fingolimod for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Tramacere, Irene
    Firwana, Belal
    Pacchetti, Ilaria
    Palumbo, Roberto
    Filippini, Graziella
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [10] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481